OT/Hi, just wanted to pass along to my friends here that there might be a good opportunity for investors with a company called Zalicus, a number of us have been studying it if you're interested. I do hold shares there, ok.
Wall Street will soon learn of three cHTS achievements and one electrophysiological achievment.
1. 5 Dec 2010 - Zalicus announces its discovery of a new medical drug combination proved effective in preclinical studies for treating Multiple Myeloma. The report will be announced at a December oncology conference in Orlando, Florida, we discovered: "enhanced efficacy" ... "at least 80-fold selectivity" ... "Substantial increases in inhibition of proliferation and cell killing" ... "2 to 100 fold potency shifts" ... "results in 95% inhibition of proliferation" ... "30 fold shift in the dexamethasone IC50" ... "combination index of 0.1 indicating high levels of synergy" ... "results in nearly complete (cancer) cell killing" ... "A2A agonists are effective in combination in cells resistant" ... "Mice bearing subcutaneous MM.1S tumors show a 43% regression in tumor volume after treatment"... This discovery is also protected by patents filed by Zalicus that has a growing proprietary platform of drug combinations available for partnership, out-licensing, and/or for sale.
2. Zalicus announces the successful completion of a cHTS cystic fibrosis study in two scholarly articles entitled: "Identification of Synergistic Combinations of F508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators" and "Optimization of a Yellow Fluorescent Protein-Based Iodide Influx High-Throughput Screening Assay for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators."
3. 10 Dec 2010 The co-founder of Fovea (Sanofi) and one of his colleagues may be announcing the successful phase 2B study of Prednisporin at an ocular conference to be held in China. The announcement will guarantee Zalicus a 3 million dollar milestone payment on the launch on phase 3 expected to begin in early 2011.
4. In December Zalicus will file its I.N.D.A. for its long awaited second generation ion channel pain blocker. Investors are eager to learn whether 1 or 2 new compounds will be filed with the FDA to commence clinical studies in early 2011.
Both Scistats and Stocklasar are pumpers as Mr. Bone in CTIC (I think Bone is still there, from $2 or 38 cents but still bullish in CTIC).
ZLCS used to be CRXX. CEO estimated royalties of 3Q was over $10M, (2ndQ got $1.1M). On 11/14, earning release of 3Q royalties is $0.1M, so CEO missed 100 times less (10M vs 0.1M). Can you trust this kind of smart CEO? I don’t know what is he good at.